Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
Hisamitsu Pharmaceutical Co., Inc. operates in the Healthcare sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for HTSUF.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). HTSUF Stock Intelligence Report. [stoxpulse.com/stocks/htsuf]
Disclaimer: The information on this page about Hisamitsu Pharmaceutical Co., Inc. (HTSUF) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Hisamitsu Pharmaceutical Co., Inc..
Join the WaitlistAI analysis is being generated. Visit the AI Intel tab for detailed analysis.
How Much Would You Have if You Had Invested $2,000...
17h ago
Tech Corner: AAPL Builds Up Tech Ecosystem
18h ago
StoxPulse AI results for HTSUF: Pulse Score 59/100. Primary sentiment trends from 15 news sources and 0 SEC filings indicate a bullish outlook.
Market Cap
$2.03B
P/E Ratio
12.5
EPS
$69.00
Volume
100
Avg Volume
—
Open
$29.00
Prev. Close
$29.00
Day Range
$29.00 - $29.00
50-Day Avg
$29.00
200-Day Avg
$28.99
52W High
$32.30
52W Low
$27.52
1D
0.0%
5D
0.0%
1M
0.0%
3M
0.0%
6M
0.0%
YTD
0.0%
1Y
+5.4%
3Y
+0.8%
5Y
-31.0%
Revenue
10.1%
Net Income
55.8%
EPS
62.7%
Free Cash Flow
-3.1%
FY 2025 vs FY 2024
Outstanding
70.1M
Float
30.1M
Free Float
43.0%
Feb 26
$0.42
Aug 25
$0.41
Feb 25
$0.30
Aug 24
$0.31
Feb 24
$0.28
Aug 23
$0.29
Feb 23
$0.31
Aug 22
$0.30
Feb 22
$0.36
Aug 21
$0.38
Feb 21
$0.39
Aug 20
$0.40
Stock Splits
Jul 24
+46.4%
Oct 24
Apr 25
Jul 25
-48.9%
Oct 25
Jan 26
+18.4%
Jan 26
+18.1%
Apr 26
Beat estimates 5 of 6 quarters (83%)
CEO
Kazuhide Nakatomi
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Website
hisamitsu.co.jpHisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.

How Much Would You Have if You Had Invested $2,000 In Apple When It Went Public?

Tech Corner: AAPL Builds Up Tech Ecosystem

Apple's 50th Anniversary Was April 1. Is the Tech Giant's Stock Worth Buying and Holding for Another 50 Years?

The Fed Held Rates Again: Why Long-Term Investors May Not Need to Do Anything

Apple at 50: The iPhone maker 'blew a 5-year lead' on AI, but former insiders say it can still win

2,057 Shares in Apple Inc. $AAPL Acquired by Demming Financial Services Corp ADV

Apple Inc. $AAPL Stake Increased by Stableford Capital II LLC

Signal Advisors Wealth LLC Acquires 50,263 Shares of Apple Inc. $AAPL